Correction: Invitation to presentation of Xbrane Biopharma’s interim report January – March 2023 on May 31, 2023

29 May 2023 - 18:50

The reason for the correction is that the previous press release was incorrectly identified as a regulatory release in accordance with (EU) 596/2014 Market Abuse Regulation (MAR).

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Wednesday, May 31th, 2023, at 11.00 a.m. CET. Xbrane will publish the company’s interim report January – March 2023, on Wednesday, May 31, 2023, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January – March 2023, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:

If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

Provided by: MFN
Nasdaq First North GM Stockholm (Sweden)
Xbrane Biopharma AB
Xbrane Biopharma develops and manufactures biosimilars and generic long-acting injectables. It offers products including Spherotide, for the treatment of prostate cancer, breast cancer, endometriosis, and myoma and Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes-related macular edema, diabetic retinopathy, and retinal vein occlusion....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More